StemCell Therapy

The 51 rating InvestorsObserver gives to Syros Pharmaceuticals Inc (SYRS) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 60 percent of stocks in the Biotechnology industry, SYRSs 51 overall rating means the stock scores better than 51 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 51 means the stock is more attractive than 51 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Syros Pharmaceuticals Inc (SYRS) stock is higher by 9.3% while the S&P 500 has fallen -0.66% as of 1:34 PM on Friday, Dec 18. SYRS has risen $1.03 from the previous closing price of $11.07 on volume of 392,085 shares. Over the past year the S&P 500 has gained 15.37% while SYRS has risen 94.53%. SYRS lost -$1.65 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Syros Pharmaceuticals Inc (SYRS) Stock.

Read more:
Is Syros Pharmaceuticals Inc (SYRS) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

This entry was posted on December 22, 2020 at 4:59 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |